IECM
LGND icon

Intrinsic Edge Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Intrinsic Edge Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,900
Closed -$1.49M – 148
2023
Q3 		$1.49M Buy
+24,900
New +$1.64M 0.17% 101
2017
Q2 		– Sell
-19,236
Closed -$1.27M – 133
2017
Q1 		$1.27M Buy
+19,236
New +$1.27M 0.39% 81

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Intrinsic Edge Capital Management's LGND Position: Q4 2023 in Review

Intrinsic Edge Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2023, closing a stake of 24,900 shares — an estimated $1.49M sold.

Intrinsic Edge Capital Management first reported a position in LGND in Q1 2017 and held it in 2 quarters. The position peaked at $1.49M in Q3 2023. 211 funds tracked by Wall St. Rank hold LGND as of Q4 2023.

  • Intrinsic Edge Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 24,900 Ligand Pharmaceuticals shares in Q4 2023, an estimated $1.49M.
  • Intrinsic Edge Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Intrinsic Edge Capital Management's Ligand Pharmaceuticals position peaked at $1.49M in Q3 2023.
  • 211 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2023.

Based on Intrinsic Edge Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.